{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T20:10:09Z","timestamp":1749931809598,"version":"3.41.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,14]]},"DOI":"10.7759\/cureus.86016","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T19:56:51Z","timestamp":1749931011000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Albumin Therapy and Paracentesis Interval in Cirrhotic Patients With Recurrent Ascites: A Prospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Muhammad Abdullah","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafiz Muhammad Faizan","family":"Mughal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shehwar","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Khaliq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul","family":"Ghafoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i41.5910","article-title":"Epidemiology of liver cirrhosis and associated complications: current knowledge and future directions","volume":"28","author":"Liu YB","year":"2022","unstructured":"Liu YB, Chen MK. Epidemiology of liver cirrhosis and associated complications: current knowledge and future directions. World J Gastroenterol. 2022, 28:5910-30. 10.3748\/wjg.v28.i41.5910","journal-title":"World J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.03.065","article-title":"Outcomes and mortality of grade 1 ascites and recurrent ascites in patients with cirrhosis","volume":"19","author":"Tonon M","year":"2021","unstructured":"Tonon M, Piano S, Gambino CG, et al.. Outcomes and mortality of grade 1 ascites and recurrent ascites in patients with cirrhosis. Clin Gastroenterol Hepatol. 2021, 19:358-66.e8. 10.1016\/j.cgh.2020.03.065","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.22048","article-title":"Daily low-volume paracentesis and clinical complications in patients with refractory ascites","volume":"6","author":"Tergast TL","year":"2023","unstructured":"Tergast TL, Griemsmann M, Stockhoff L, et al.. Daily low-volume paracentesis and clinical complications in patients with refractory ascites. JAMA Netw Open. 2023, 6:e2322048. 10.1001\/jamanetworkopen.2023.22048","journal-title":"JAMA Netw Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-024-01315-1","article-title":"Role of albumin infusion in cirrhosis-associated complications","volume":"24","author":"Heybe MA","year":"2024","unstructured":"Heybe MA, Mehta KJ. Role of albumin infusion in cirrhosis-associated complications. Clin Exp Med. 2024, 24:58. 10.1007\/s10238-024-01315-1","journal-title":"Clin Exp Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.03.005","article-title":"Long-term albumin treatment in patients with cirrhosis and ascites","volume":"76","author":"Caraceni P","year":"2022","unstructured":"Caraceni P, O'Brien A, Gines P. Long-term albumin treatment in patients with cirrhosis and ascites. J Hepatol. 2022, 76:1306-17. 10.1016\/j.jhep.2022.03.005","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00279-0","article-title":"Managing cirrhosis with limited resources: perspectives from sub-Saharan Africa","volume":"9","author":"Sonderup MW","year":"2024","unstructured":"Sonderup MW, Kamath PS, Awuku YA, et al.. Managing cirrhosis with limited resources: perspectives from sub-Saharan Africa. Lancet Gastroenterol Hepatol. 2024, 9:170-84. 10.1016\/S2468-1253(23)00279-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2024-1-1","article-title":"Cost-effectiveness of albumin in the treatment of decompensated cirrhosis in resource-limited healthcare settings","volume":"13","author":"Hasan I","year":"2024","unstructured":"Hasan I, Murti IS, Bayupurnama P, Kalista KF, Hill-Zabala C, Kananda D, Viayna E. Cost-effectiveness of albumin in the treatment of decompensated cirrhosis in resource-limited healthcare settings. Drugs Context. 2024, 13:2024-1-1. 10.7573\/dic.2024-1-1","journal-title":"Drugs Context"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15253","article-title":"Long-term albumin administration in patients with cirrhosis and ascites: a meta-analysis of randomized controlled trials","volume":"36","author":"Sandi BB","year":"2021","unstructured":"Sandi BB, Le\u00e3o GS, de Mattos AA, de Mattos \u00c2Z. Long-term albumin administration in patients with cirrhosis and ascites: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2021, 36:609-17. 10.1111\/jgh.15253","journal-title":"J Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.2880","article-title":"Effectiveness of resource groups for improving empowerment, quality of life, and functioning of people with severe mental illness: a randomized clinical trial","volume":"78","author":"Tjaden C","year":"2021","unstructured":"Tjaden C, Mulder CL, den Hollander W, et al.. Effectiveness of resource groups for improving empowerment, quality of life, and functioning of people with severe mental illness: a randomized clinical trial. JAMA Psychiatry. 2021, 78:1309-18. 10.1001\/jamapsychiatry.2021.2880","journal-title":"JAMA Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09336-3","article-title":"Feasibility of a fast-track randomized controlled trial of cell-free and concentrated ascites reinfusion therapy for patients with refractory malignant ascites","volume":"22","author":"Yokomichi N","year":"2022","unstructured":"Yokomichi N, Imai K, Sakamoto M, et al.. Feasibility of a fast-track randomized controlled trial of cell-free and concentrated ascites reinfusion therapy for patients with refractory malignant ascites. BMC Cancer. 2022, 22:218. 10.1186\/s12885-022-09336-3","journal-title":"BMC Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i33.4773","article-title":"Albumin administration in patients with cirrhosis: current role and novel perspectives","volume":"28","author":"de Mattos \u00c2Z","year":"2022","unstructured":"de Mattos \u00c2Z, Simonetto DA, Terra C, et al.. Albumin administration in patients with cirrhosis: current role and novel perspectives. World J Gastroenterol. 2022, 28:4773-86. 10.3748\/wjg.v28.i33.4773","journal-title":"World J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.10.016","article-title":"AGA clinical practice update on the use of vasoactive drugs and intravenous albumin in cirrhosis: expert review","volume":"166","author":"Garcia-Tsao G","year":"2024","unstructured":"Garcia-Tsao G, Abraldes JG, Rich NE, Wong VW. AGA clinical practice update on the use of vasoactive drugs and intravenous albumin in cirrhosis: expert review. Gastroenterology. 2024, 166:202-10. 10.1053\/j.gastro.2023.10.016","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17344","article-title":"Meta-analysis: efficacy and safety of albumin in the prevention and treatment of complications in patients with cirrhosis","volume":"57","author":"Leache L","year":"2023","unstructured":"Leache L, Guti\u00e9rrez-Valencia M, Saiz LC, et al.. Meta-analysis: efficacy and safety of albumin in the prevention and treatment of complications in patients with cirrhosis. Aliment Pharmacol Ther. 2023, 57:620-34. 10.1111\/apt.17344","journal-title":"Aliment Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101150","article-title":"Intravenous albumin in cirrhosis: updated clinical uses and novel perspectives","volume":"28","author":"Gagliardi R","year":"2023","unstructured":"Gagliardi R, Zeni N, Piano S. Intravenous albumin in cirrhosis: updated clinical uses and novel perspectives. Ann Hepatol. 2023, 28:101150. 10.1016\/j.aohep.2023.101150","journal-title":"Ann Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100785","article-title":"Use of albumin infusion for cirrhosis-related complications: an international position statement","volume":"5","author":"Bai Z","year":"2023","unstructured":"Bai Z, M\u00e9ndez-S\u00e1nchez N, Romeiro FG, et al.. Use of albumin infusion for cirrhosis-related complications: an international position statement. JHEP Rep. 2023, 5:100785. 10.1016\/j.jhepr.2023.100785","journal-title":"JHEP Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2023.0024","article-title":"Hepatorenal syndrome: current concepts and future perspectives","volume":"29","author":"Jung CY","year":"2023","unstructured":"Jung CY, Chang JW. Hepatorenal syndrome: current concepts and future perspectives. Clin Mol Hepatol. 2023, 29:891-908. 10.3350\/cmh.2023.0024","journal-title":"Clin Mol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000521","article-title":"Controversies regarding albumin therapy in cirrhosis","volume":"81","author":"Trebicka J","year":"2025","unstructured":"Trebicka J, Garcia-Tsao G. Controversies regarding albumin therapy in cirrhosis. Hepatology. 2025, 81:288-303. 10.1097\/HEP.0000000000000521","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022166","article-title":"A randomized trial of albumin infusions in hospitalized patients with cirrhosis","volume":"384","author":"China L","year":"2021","unstructured":"China L, Freemantle N, Forrest E, et al.. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med. 2021, 384:808-17. 10.1056\/NEJMoa2022166","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/377360-assessment-of-albumin-therapy-and-paracentesis-interval-in-cirrhotic-patients-with-recurrent-ascites-a-prospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T19:56:52Z","timestamp":1749931012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/377360-assessment-of-albumin-therapy-and-paracentesis-interval-in-cirrhotic-patients-with-recurrent-ascites-a-prospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,14]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.86016","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,14]]}}}